News & Events > class visitor kirsten detrick t92 executive director of global marketing co
Class Visitor: Kirsten Detrick, T’92 - Executive Director of Global Marketing & Commercial Development, Amgen, Inc.
- Date: 18 Apr
- Location: Shapiro Classroom, Tuck School
- Time: 3:00 p.m.
Kirsten Detrick, T'92 is the Executive Director of Global Marketing & Commercial Development at Amgen, Inc. She will serve as a visiting executive in Professor Paul Gardent's and Professor Mike Zubkoff's Structure, Organization and Economics of the Health Care Industry spring elective course. Ms. Detrick will speak on the topic of "Biotechnology: Bringing Tomorrow's Science to Today's Health Care Challenges."
Kirsten Detrick is an Executive Director of Global Marketing and Commercial Development at Amgen Inc., a leading human therapeutics company in Southern California. In this role, Kirsten is currently building commercialization strategies for Japan and emerging markets, for a molecule in Amgen’s phase 1 pipeline that is being investigated for the treatment of hypercholesterolemia. She is also leading a team that is analyzing commercial opportunities in Japan for a range of additional molecules in Amgen’s mid- to late-stage pipeline, across a wide range of therapeutic areas including oncology, diabetes, schizophrenia, inflammation and bone.
Most recently, Kirsten was Brand Lead for Prolia® (denosumab), a first-in-class human monoclonal antibody for postmenopausal osteoporosis. One of the first biologics to be targeted at primary care physicians, the product launched in June 2010 and is forecasted to achieve >$1 billion in peak global sales potential (Wall Street estimate).
Kirsten joined Amgen in 2004 as Senior Director of Enbrel® Rheumatology Sales and Marketing, leading a team of over 100 Amgen sales and marketing professionals in a joint venture/co-promote structure with Wyeth Pharmaceuticals. In addition to this role, Kirsten led dermatology (psoriasis) marketing for Enbrel® and also partnered with regulatory and clinical development colleagues to generate additional data and indications for the therapeutic.
Prior to joining Amgen, Kirsten was with Bristol-Myers Squibb (BMS). From 2002-2004, she supervised the Plavix® US primary care marketing team, in a joint venture with Sanofi-Synthelabo. Today, Plavix is the 2nd best-selling drug in any category, worldwide. Kirsten developed US commercialization plans for a BMS first-in-class anti-hypertensive drug (Vanlev™) from 1999-2002, and from 1997-1999, Kirsten developed and institutionalized a global Marketing Analysis and Planning (MAP) process for BMS. Authoring a 40+ page proprietary guidebook on the process, Kirsten and her team developed and delivered a series of weeklong instructional courses for approximately 1,000 cross-functional BMS executives worldwide. Kirsten began her career at BMS in 1991 with the Worldwide Consumer Medicines Division, working on OTC drugs including Excedrin®, Bufferin®, and Nuprin®.
From 1987 to 1990, Kirsten was a management consultant with APM Incorporated in New York City, where she analyzed, designed and executed strategic and operational improvements for US hospitals and medical centers. In 1990, Kirsten was a Legislative Fellow for US Senate Majority Leader George J. Mitchell in Washington, DC, where she analyzed healthcare cost-containment options for a Senate sub-committee and developed Medicare and Medicaid legislative proposals.
Kirsten earned her Bachelor of Arts (BA) in chemistry from Middlebury College and her Master of Business Administration (MBA) from the Amos Tuck School of Business at Dartmouth College.
Kirsten is a member of the Healthcare Businesswomen’s Association (HBA), and was a recipient of an “HBA Rising Star” award in 2000.Back to Events List